Search Results 141-150 of 1012 for ���������������������������������������������:PC90���
TRK-250 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor- ...
This randomized phase III trial compares memantine hydrochloride and whole-brain radiotherapy with or without hippocampal avoidance in reducing ...
Collection of tissue and blood from patients with residual disease after neoadjuvant systemic therapy for breast cancer. We hope to use these samples to ...
The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
All of Us Research Program Genomics Investigators. Genomic data in the All of Us Research Program. Nature. 2024 Mar; 627 (8003):340-346 Epub 2024 Feb 19
The study will evaluate avatrombopag in the treatment of thrombocytopenia associated with liver disease prior to an elective procedure to reduce the need for ...
More than 63,000 employees of Mayo Clinic drive the engine of the organization's patient-centered mission, advance important research and.
The purpose of this study is to evaluate ways to reduce the number of complications (problems) related to inserting a catheter (a small flexible tube) into a ...
A Study to Evaluate Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma · Share ...
About this study. RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
The challenge ends 10/10. Your gift today can have 5X the impact on AI research and technology.